Close Menu

BMS

The firm said that adjuvant nivolumab had benefitted patients regardless of PD-L1 expression, and that the company will submit the data to regulatory agencies.

Data from ESMO positioned the competing checkpoint inhibitors as potential new standards of care in the first-line setting, but biomarker questions remain.

The European Commission will now consider CHMP's opinion and decide whether to approve the regimen as a first-line option for metastatic NSCLC patients without EGFR or ALK alterations.

Once finalized, lung cancer patients in England can receive the drug for two years after they've received chemotherapy and if their tumors express PD-L1.

The CheckMate-650 trial showed the potential of combined immunotherapy in metastatic, castration-resistant prostate cancer and identified subgroups for further study.  

The company said it is evaluating the full data from the IDHENTIFY trial and will present the analysis at an upcoming medical conference.

Therapy was most effective in patients with a diverse baseline repertoire of T cell receptors and an associated expansion of singleton clones during treatment.

Idecabtagene vicleucel is a B-cell maturation antigen-directed CAR T-cell immunotherapy being developed as a treatment for patients with relapsed and refractory multiple myeloma.

Formerly the data analytics division of CTCA, Vidence is supporting an immuno-oncology trial for BMS as it looks to grow its network of hospital partners.

The partners will use ReviveMed's AI-driven platform to better understand mechanisms of immunotherapy response and resistance in cancer patients.

Pages